{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:38:40Z","timestamp":1789958320811,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.euo.2018.07.010","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T19:25:53Z","timestamp":1535052353000},"page":"214-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes"],"prefix":"10.1016","volume":"2","author":[{"given":"Sabina","family":"Davidsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giunchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Harlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kirrander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ove","family":"Andr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2018.07.010_bib0165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.urology.2015.12.041","article-title":"Management of penile cancer","volume":"96","author":"Diorio","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.euo.2018.07.010_bib0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2490-9-8","article-title":"Identifying the needs of penile cancer sufferers: a systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer","volume":"9","author":"Maddineni","year":"2009","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2018.07.010_bib0175","doi-asserted-by":"crossref","first-page":"785","DOI":"10.21037\/tau.2017.05.19","article-title":"Updates on the epidemiology and risk factors for penile cancer","volume":"6","author":"Douglawi","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2018.07.010_bib0180","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.euo.2018.07.010_bib0185","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2018.07.010_bib0190","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1073\/pnas.0307252101","article-title":"PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells","volume":"101","author":"Latchman","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euo.2018.07.010_bib0195","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.euo.2018.07.010_bib0200","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2018.07.010_bib0205","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/cncr.25747","article-title":"Overall survival and PD-L1 expression in metastasized malignant melanoma","volume":"117","author":"Gadiot","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2018.07.010_bib0210","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdv009","article-title":"Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma","volume":"26","author":"Bellmunt","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2018.07.010_bib0215","doi-asserted-by":"crossref","first-page":"33972","DOI":"10.18632\/oncotarget.5583","article-title":"High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer","volume":"6","author":"Qin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2018.07.010_bib0220","doi-asserted-by":"crossref","unstructured":"Ren M, Dai B, Kong YY, Lv JJ, Cai X. PD-L1 expression in tumor infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients. Histopathology. In press. https:\/\/doi.org\/10.1111\/his.13527.","DOI":"10.1111\/his.13527"},{"key":"10.1016\/j.euo.2018.07.010_bib0225","doi-asserted-by":"crossref","first-page":"11671","DOI":"10.1038\/s41598-017-11905-7","article-title":"Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value","volume":"7","author":"Kim","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2018.07.010_bib0230","doi-asserted-by":"crossref","first-page":"83986","DOI":"10.18632\/oncotarget.20233","article-title":"Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2018.07.010_bib0235","doi-asserted-by":"crossref","first-page":"58457","DOI":"10.18632\/oncotarget.17022","article-title":"PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2018.07.010_bib0240","doi-asserted-by":"crossref","first-page":"36956","DOI":"10.1038\/srep36956","article-title":"PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients","volume":"6","author":"Kim","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2018.07.010_bib0245","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.3892\/or.2015.3933","article-title":"The prognostic significance of PD-L1 in bladder cancer","volume":"33","author":"Huang","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.euo.2018.07.010_bib0250","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2018.07.010_bib0255","doi-asserted-by":"crossref","first-page":"234","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2018.07.010_bib0260","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2018.07.010_bib0265","doi-asserted-by":"crossref","first-page":"e1269047","DOI":"10.1080\/2162402X.2016.1269047","article-title":"Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma","volume":"6","author":"Deng","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.euo.2018.07.010_bib0270","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2016.09.003","article-title":"Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort","volume":"59","author":"Cocks","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.euo.2018.07.010_bib0275","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.juro.2016.09.088","article-title":"Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status","volume":"197","author":"Ottenhof","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2018.07.010_bib0280","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2007.09.009","article-title":"Real-time Taqman PCR targeting 14 human papilloma virus types","volume":"40","author":"Lindh","year":"2007","journal-title":"J Clin Virol"},{"key":"10.1016\/j.euo.2018.07.010_bib0285","first-page":"14595","article-title":"Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis","volume":"8","author":"Xu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.euo.2018.07.010_bib0290","doi-asserted-by":"crossref","first-page":"8944","DOI":"10.18632\/oncotarget.6884","article-title":"Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas","volume":"7","author":"Zeng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2018.07.010_bib0295","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JTO.0000000000000414","article-title":"Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer","volume":"10","author":"Ishii","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.euo.2018.07.010_bib0300","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.euo.2018.07.010_bib0305","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejso.2015.01.020","article-title":"The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis","volume":"41","author":"Wang","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.euo.2018.07.010_bib0310","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2018.07.010_bib0315","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2018.07.010_bib0320","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931118301184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931118301184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:44:57Z","timestamp":1762875897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931118301184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2588931118301184"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2018.07.010","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2018.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}